Kiniksa Pharmaceuticals, Ltd. Contracts & Agreements

Sixth Amendment of Sublease, dated May 24, 2023, by and between Kiniksa Pharmaceuticals Corp. and 92 Hayden Avenue Trust (Filed With SEC on August 1, 2023)

Fifth Amendment of Sublease, dated July 27, 2022, by and between Kiniksa Pharmaceuticals Corp. and 92 Hayden Avenue Trust (Filed With SEC on November 3, 2022)

Amendment No. 2, dated August 2, 2022, to the Asset Purchase Agreement, dated September 7, 2016, by and between the Registrant and Biogen MA Inc (Filed With SEC on November 3, 2022)

License Agreement, dated August 2, 2022, by and among Kiniksa Pharmaceuticals (UK), Ltd., Genentech, Inc. and F. Hoffmann-La Roche Ltd (Filed With SEC on November 3, 2022)

Amended and Restated Employment Agreement, effective as of February 1, 2022, by and between Ross Moat and Kiniksa Pharmaceuticals (UK), Ltd (Filed With SEC on February 24, 2022)

Change in Control Agreement, effective as of January 3, 2022, by and between Michael Megna and Kiniksa Pharmaceuticals Corp (Filed With SEC on February 24, 2022)

Letter Agreement, dated as of February 1, 2022, by and between Ross Moat and Kiniksa Pharmaceuticals, Ltd (Filed With SEC on February 24, 2022)

Employment Agreement, effective as of April 1, 2021, by and between Arian Pano and Kiniksa Pharmaceuticals Corp (Filed With SEC on February 24, 2022)

Separation Agreement, effective as of February 3, 2022, by and between Arian Pano and Kiniksa Pharmaceuticals Corp (Filed With SEC on February 24, 2022)

Exclusive License Agreement, dated as of November 1, 2013, by and between The Beth Israel Deaconess Medical Center and Primatope Therapeutics Inc (Filed With SEC on February 24, 2022)

Amended and Restated Employment Agreement, effective as of January 3, 2022, by and between Eben Tessari and Kiniksa Pharmaceuticals Corp (Filed With SEC on January 3, 2022)

Non-Employee Director Compensation Program (Filed With SEC on May 6, 2021)

Employment Agreement, effective as of April 1, 2021, by and between the Company and Mark Ragosa (Filed With SEC on May 6, 2021)

Amendments Nos. 1 and 2 to the License Agreement, dated September 25, 2017, by and between Kiniksa Pharmaceuticals and Regeneron Pharmaceuticals, Inc (Filed With SEC on May 6, 2021)

Commercial Supply Agreement, dated February 26, 2021, by and between Kiniksa Pharmaceuticals (UK) Ltd. and Regeneron Pharmaceuticals, Inc (Filed With SEC on May 6, 2021)

Restricted Share Agreement, dated as of September 18, 2015, by and between Kiniksa Pharmaceuticals, Ltd. and Thomas Beetham (Filed With SEC on February 25, 2021)

Amended and Restated Employment Agreement, dated as of May 29, 2018, by and between Kiniksa Pharmaceuticals Corp. and Thomas Beetham (Filed With SEC on February 25, 2021)

Offering Document under the 2018 Employee Share Purchase Plan (effective January 1, 2021) (Filed With SEC on February 25, 2021)

Offering Document under the 2018 Employee Share Purchase Plan (effective July 1, 2019) (Filed With SEC on February 25, 2021)

Recognition and Attornment Agreement and Amendment of Sublease by and between Kiniksa Pharmaceuticals Corp. and 92 Hayden Avenue Trust dated as of November 6, 2020 (Filed With SEC on November 10, 2020)

Underwriting Agreement, dated July 21, 2020, by and among the Company and Goldman Sachs & Co. LLC, BofA Securities, Inc. and J.P. Morgan Securities LLC, as representatives of the... (Filed With SEC on July 24, 2020)

Amendment No. 1 to the License Agreement, effective as of July 9, 2020, by and between Kiniksa Pharmaceuticals, Ltd. and MedImmune Limited (Filed With SEC on July 15, 2020)

Underwriting Agreement, dated May 13, 2020, by and among the Company and Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and BofA Securities, Inc., as representatives of the... (Filed With SEC on May 18, 2020)

2018 Incentive Award Plan, and the form of share option grant notice and option agreement, form of restricted share grant notice and restricted share agreement, and form of... (Filed With SEC on May 4, 2020)

Employment agreement, dated August 20, 2018, by and between Kiniksa Pharmaceuticals Corp. and Qasim Rizvi (Filed With SEC on March 5, 2020)

Letter Agreement, dated November 13, 2019, between Kiniksa Pharmaceuticals, Ltd. and Stephen Mahoney (Filed With SEC on March 5, 2020)

Description of Kiniksa Pharmaceuticals, Ltd. Securities (Filed With SEC on March 5, 2020)

Form of Restricted Share Unit Grant Notice and Agreement under the Rilonacept Long-Term Incentive Plan (Filed With SEC on December 16, 2019)

Kiniksa Pharmaceuticals, Ltd. Rilonacept Long-Term Incentive Plan (Filed With SEC on December 16, 2019)

Form of Performance Restricted Share Unit and Performance Cash Award Grant Notice and Agreement under the Rilonacept Long-Term Incentive Plan (Filed With SEC on December 16, 2019)

Non-Employee Director Compensation Program (as amended October 1, 2019) (Filed With SEC on November 5, 2019)

2018 Incentive Award Plan forms of share option grant notice and share option agreement for German participants, restricted share grant notice and restricted share agreement for... (Filed With SEC on March 12, 2019)

Form of Underwriting Agreement (Filed With SEC on January 28, 2019)

Amended and Restated Employment Agreement, dated as of May 29, 2018, by and between Kiniksa Pharmaceuticals Corp. and Thomas Beetham (Filed With SEC on January 28, 2019)

Amended and Restated Employment Agreement, dated as May 29, 2018, by and between Kiniksa Pharmaceuticals Corp. and Chris Heberlig (Filed With SEC on January 28, 2019)

Amended and Restated Employment Agreement, dated as of May 29, 2018, by and between Kiniksa Pharmaceuticals Corp. and Carsten Boess (Filed With SEC on January 28, 2019)

Amended and Restated Employment Agreement, dated as May 29, 2018, by and between Kiniksa Pharmaceuticals Corp. and Rasmus Holm-Jorgensen (Filed With SEC on January 28, 2019)

2018 Incentive Award Plan, and the form of share option grant notice and option agreement, form of restricted share grant notice and restricted share agreement, and form of... (Filed With SEC on January 28, 2019)

Offering Document under the 2018 Employee Share Purchase Plan (Filed With SEC on January 28, 2019)

2018 Incentive Award Plan; Sub-Plan for UK Employees, and the form of share option grant notice for UK participants (Filed With SEC on January 28, 2019)

Restricted Share Agreement, dated as of September 16, 2015, by and between the Registrant and Sanj K. Patel (Filed With SEC on January 28, 2019)

Restricted Share Agreement, dated as of September 18, 2015, by and between the Registrant and Stephen Mahoney (Filed With SEC on January 28, 2019)

Third Amendment to Sublease Agreement, effective as of November 7, 2018 by and between Kiniksa Pharmaceuticals Corp. and Shire Human Genetic Therapies, Inc (Filed With SEC on November 13, 2018)

2018 Incentive Award Plan (Filed With SEC on August 6, 2018)

Form of Share Option Grant Notice and Share Option Agreement under the 2018 Incentive Award Plan (Filed With SEC on August 6, 2018)

Form of Restricted Share Grant Notice and Restricted Share Agreement under the 2018 Incentive Award Plan (Filed With SEC on August 6, 2018)

Form of Restricted Share Unit Grant Notice and Restricted Share Unit Agreement under the 2018 Incentive Award Plan (Filed With SEC on August 6, 2018)

2018 Employee Share Purchase Plan (Filed With SEC on August 6, 2018)

Offering Document under the 2018 Employee Share Purchase Plan (Filed With SEC on August 6, 2018)

Amended and Restated Employment Agreement, dated as of May 29, 2018, by and between Kiniksa Pharmaceuticals Corp. and Sanj K. Patel (Filed With SEC on August 6, 2018)

Amended and Restated Employment Agreement, dated as of May 29, 2018, by and between Kiniksa Pharmaceuticals Corp. and Stephen Mahoney (Filed With SEC on August 6, 2018)

Amended and Restated Employment Agreement, dated as of May 29, 2018, by and between Kiniksa Pharmaceuticals Corp. and John F. Paolini (Filed With SEC on August 6, 2018)

First and Second Amendment to Sublease Agreement, dated as of June 26, 2018 and July 17, 2018, respectively, by and between Kiniksa Pharmaceuticals Corp. and Shire Human Genetic... (Filed With SEC on August 6, 2018)